Biochemical control of the combination of cyclooxygenase-2 inhibitor and
biochemical control
cyclooxygenase-2 inhibitor
low-dose-rate brachytherapy
prostate cancer
radiation therapy
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
08
01
2020
accepted:
25
05
2020
pubmed:
27
6
2020
medline:
28
4
2021
entrez:
27
6
2020
Statut:
ppublish
Résumé
To evaluate the use of cyclooxygenase-2 inhibitors in patients receiving low-dose-rate brachytherapy for prostate cancer. A total of 310 patients with prostate cancer (cT1c-3aN0M0) who received low-dose-rate brachytherapy between May 2010 and July 2013 were enrolled and allocated to one of the two treatment groups (tamsulosin alone 0.2 mg/day for 6 months vs tamsulosin 0.2 mg/day for 6 months plus celecoxib 200 mg/day for 3 months). The primary end-point was the chronological change in international prostate symptom score, and the number of patients was assessed for the primary end-point. Biochemical recurrence-free, cancer-specific survival and overall survival rates 5 years after the last patient received low-dose-rate brachytherapy were retrospectively examined. The median follow-up period after low-dose-rate brachytherapy was 72.0 months (range 3-99 months). A total of 12 (3.9%) patients experienced biochemical recurrence. The biochemical recurrence-free rate in the celecoxib group (5-year biochemical recurrence-free rate 98.5%) was significantly better (log-rank test P = 0.023, 95% confidence interval 0.07-0.63, hazard ratio 0.20) than that in the tamsulosin group (5-year biochemical recurrence-free rate 93.4%). None of the patients died from prostate cancer. However, 14 (4.5%) patients died of other causes. No significant difference was observed in terms of overall survival between the celecoxib and tamsulosin groups. The combination of cyclooxygenase-2 inhibitor and low-dose-rate brachytherapy can contribute to a better biochemical control of prostate cancer.
Substances chimiques
Cyclooxygenase 2 Inhibitors
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
755-759Informations de copyright
© 2020 The Japanese Urological Association.
Références
Zimmermann KC, Sarbia M, Weber AA et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999; 59: 198-204.
Ristimäki A, Honkanen N, Jänkälä H et al. Expression of cyclooxygenase-2 in human gastric caricinoma. Cancer Res. 1997; 57: 1276-80.
Sano H, Kawahito Y, Wilder RL et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995; 55: 3785-9.
Hida T, Yatabe Y, Achiwa H et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998; 58: 3761-4.
Rubio J, Ramos D, Lopez-Guerrero JA et al. Immunohistochemical expression of Ki-67 antigen, COX-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur. Urol. 2005; 48: 745-51.
Khor LY, Bae K, Pollack A et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol. 2007; 8: 912-20.
Dandekar DS, Lokeshwar BL. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormonerefractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin. Cancer Res. 2004; 10: 8037-47.
Wen B, Deutsch E, Eschwege P et al. Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells. J. Urol. 2003; 170: 2036-9.
Pyo H, Choy H, Amorino GP et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin. Cancer Res. 2001; 7: 2998-3005.
Anai S, Tanaka M, Shiverick KT et al. Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells. J. Urol. 2007; 177: 1913-7.
Inoue T, Anai S, Onishi S et al. Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model. BMC Urol. 2013; 13: 1.
Grimm P, Billiet I, Bostwick D et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012; 109: 22-9.
Kuban DA, Levy LB, Cheung MR et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int. J. Radiat. Oncol. Biol. Phys. 2011; 79: 1310-7.
Nakai Y, Tanaka N, Asakawa I et al. Quality of life in patients who underwent 125I brachytherapy, 125I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer. J. Radiat. Res. 2019; 60: 270-80.
Tanaka N, Torimoto K, Asakawa I et al. Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor. Brachytherapy 2018; 17: 537-43.
Nakai Y, Tanaka N, Asakawa I et al. Analysis of quality of life after randomized controlled trial of alpha-1 andrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer. J. Contemp. Brachytherapy 2019; 11: 409-16.
Decucquoy A, Roels S, Goethals L et al. Double blind randomized phase Ⅱ study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer. Radiother. Oncol. 2009; 93: 273-8.
Gore E, Bae K, Langer C et al. Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213. Clin. Lung Cancer 2011; 12: 125-30.
De Ruysscher D, Wanders R, van Haren E et al. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008; 71: 132-8.
Penas-Prado M, Hess KR, Fisch MJ et al. Randomized phase Ⅱ adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblstoma. Neuro-Oncology 2015; 17: 266-73.
Mohammadianpanah M, Razmjou-Ghalaei S, Shafizad A et al. Efficacy and safety concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: a phase Ⅱ-Ⅲ clinical trial. Cancer Res. Ther. 2011; 7: 442-7.
Cleary JM, Mamon HJ, Szymonifka J et al. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer 2016; 16: 468.
Morak MJ, Richel DJ, van Eijck CH et al. Phase Ⅱ trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. Radiother. Oncol. 2011; 98: 261-4.
Stock RG, Buckstein M, Liu JT et al. The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes. BJU Int. 2013; 112: 44-55.
Morris WJ, Keyes M, Palma D et al. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Urology 2009; 73: 860-7.
King L, Christie D, Arora D, Anoopkumar-Dukie S. Cyclooxygenase-2 inhibitors delay relapse and reduce prostate specific antigen (PSA) velocity in patients treated with radiotherapy for nonmetastatic prostate cancer: a pilot study. Prostate Int. 2020; 8: 34-40.